Acrivon Therapeutics, Inc. Common Stock (ACRV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.28 Million) by net assets ($128.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Acrivon Therapeutics, Inc. Common Stock (ACRV) net asset quality to measure how much of total assets are equity-financed.
Acrivon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Acrivon Therapeutics, Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
Acrivon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acrivon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Generic Sweden publ AB
ST:GENI
|
0.190x |
|
CSL Finance Limited
NSE:CSLFINANCE
|
-0.081x |
|
Immutep Limited
F:YP1A
|
-0.119x |
|
Maytronics
TA:MTRN
|
0.215x |
|
Single Well Industrial
TWO:3490
|
0.009x |
|
Stem Inc
NYSE:STEM
|
0.031x |
|
Papilon Savunma Guvenlik Sistemleri
IS:PAPIL
|
-0.031x |
|
Element 25 Ltd
AU:E25
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see ACRV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $176.79 Million | $-65.67 Million | -0.371x | -5.58% |
| 2023-12-31 | $121.19 Million | $-42.64 Million | -0.352x | -99.16% |
| 2022-12-31 | $170.47 Million | $-30.12 Million | -0.177x | -130.08% |
| 2021-12-31 | $-23.81 Million | $-13.98 Million | 0.587x | +76.26% |
| 2020-12-31 | $-8.41 Million | $-2.80 Million | 0.333x | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more